Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
BioSpace3d
Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar
Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...
Novo Nordisk A/S (NVO): Among the Best Drug Stocks to Buy Now
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
2 Important Insights From Novo Nordisk's Earnings Call
Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Yahoo Finance15d
Novo Nordisk defends next-gen obesity drug CagriSema, details new trial
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors ...
NBC 10 Philadelphia15d
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
It's been a rocky few months for Novo Nordisk. Prescription data from IQVIA suggests Novo's obesity drug Wegovy is losing ground to rival Zepbound from Eli Lilly. Wegovy's potential successor ...
This is Money15d
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...